Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Clinical Innovations hires Carl Rickenbaugh as VP of business development and strategy

April 29, 2019 GMT

SALT LAKE CITY--(BUSINESS WIRE)--Apr 29, 2019--Clinical Innovations, one of the world’s largest medical device companies focused on labor and delivery, as well as neonatal intensive care, announced today it has hired Carl Rickenbaugh as vice president of business development and strategy.

Rickenbaugh, a medical device industry veteran with decades of experience building businesses through strategic acquisitions, will be responsible for accelerating Clinical Innovations’ global M&A strategy. He has served on boards of med-tech startups, and previously led business development as Vice President of New Business Development at Bard Peripheral Vascular, preceded by positions of increasing commercial development responsibility at Abbott Laboratories.


“Continuing to grow through product acquisitions is critical to our strategy, which directly leverages our expanding commercial organization,” said Ken Reali, president and CEO of Clinical Innovations. “Carl’s deep business development experience and proven track record make him well-suited to help us advance those goals. We are excited for Carl to join Clinical Innovations and bring a consistent focus to our business development efforts.”

Clinical Innovations, with a presence in more than 90 countries, has quickly expanded through numerous acquisitions and market entries in recent years. Based in Salt Lake City and owned by leading investment firm EQT, Clinical Innovations develops and manufactures market-leading products such as the ROM Plus® Rupture of Membranes Test, traxi® Panniculus Retractor, Kiwi® Vacuum-Assisted Delivery System and Koala® Intrauterine Pressure Catheter. In 2018 alone, the company expanded operations in France, China, Australia and the United States, furthering the company’s ability to support its mission of helping mothers, babies and the physicians who treat them.

“Clinical Innovations has succeeded because of its talented employees, industry-leading products and sound strategy,” Rickenbaugh said. “I’m honored to be joining the team and look forward to building on its strong M&A momentum.”

Rickenbaugh holds a bachelor’s and a master’s degree from the University of Cincinnati and an MBA from Georgetown University.

About Clinical Innovations


Clinical Innovations is one of the largest medical device companies exclusively focused on labor and delivery and neonatal intensive care. The company is a market-leader in several categories with products such as the Koala® Intrauterine Pressure Catheter, Kiwi® Vacuum-Assisted Delivery System, ROM Plus® Rupture of Membranes Test, traxi® Panniculus Retractor, ClearView® Uterine Manipulator and the babyLance™ Safety heel stick. Clinical Innovations is expanding its global presence while directly researching and developing state-of-the-art technologies and innovative medical devices that fulfill its mission of improving the lives of mothers and their babies throughout the world. Clinical Innovations is an EQT portfolio company. For more information, visit

About EQT

EQT is a leading investment firm with approximately EUR 61 billion in raised capital across 29 funds. EQT funds have portfolio companies in Europe, Asia and the U.S. with total sales of more than EUR 19 billion and approximately 110,000 employees. EQT is an active investor and owner in the health care sector, including investments in Certara, Press Ganey, Ottobock, Sivantos, and Lima. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. For more information, visit

View source version on

CONTACT: Ashley Dennison, Aileron Communications




SOURCE: Clinical Innovations

Copyright Business Wire 2019.

PUB: 04/29/2019 06:00 AM/DISC: 04/29/2019 06:00 AM